NCT02558400View on ClinicalTrials.gov

Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

718

Participants

Timeline

Start Date

September 18, 2015

Primary Completion Date

May 17, 2017

Study Completion Date

June 30, 2017

Conditions
Open-angle GlaucomaOcular Hypertension
Interventions
DRUG

PG324 Ophthalmic Solution 0.02%/0.005%

1 drop once daily (QD), in the evening (PM) in both eyes (OU)

DRUG

Netarsudil (AR-13324) Ophthalmic Solution 0.02%

1 drop once daily (QD), in the evening (PM) in both eyes (OU)

DRUG

Latanoprost Ophthalmic Solution 0.005%

1 drop once daily (QD), in the evening (PM) in both eyes (OU)

Trial Locations (1)

07921

Aerie Pharmaceuticals, Bedminster

Sponsors
All Listed Sponsors
lead

Aerie Pharmaceuticals

INDUSTRY

NCT02558400 - Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension | Biotech Hunter | Biotech Hunter